Johnson & Johnson (BSP:JNJB34)
R$ 60.12 0 (0%) Market Cap: 2.18 Til Enterprise Value: 2.27 Til PE Ratio: 24.52 PB Ratio: 5.08 GF Score: 76/100

Johnson & Johnson at Credit Suisse Healthcare Conference (Virtual) Transcript

Nov 11, 2020 / 04:45PM GMT
Release Date Price: R$53.41 (-0.55%)
Matt Miksic
Credit Suisse - Analyst

Great. So I think we're live. Thanks, everyone, for joining us. We are very, very pleased to have with us today a team from Johnson & Johnson, Joaquin Duato, Vice Chairman, Chairman of Executive Committee; and Thibaut Mongon, who's EVP of Worldwide, Chairman of Consumer. So plenty to talk about in pharma and research, plenty to talk about in consumer.

Questions & Answers

Matt Miksic;Joaquin Duato
Credit Suisse - Analyst;Johnson & Johnson -

We're going to sort of jump right into some broad topics, since most of the folks, I think, joining us have some familiarity with J&J. But maybe to get it out of the way early, there's been a lot of news this week on vaccines. So maybe, Joaquin, if you could take a minute to sort of give us your overview, updated thoughts or next steps, and sort of a rough time line of where your program stands. Thoughts, if you have any, on the results and progress that others are making, I'm sure everyone would be interested in that type of update.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot